Alkem Laboratories has delivered a strong set of numbers for the first quarter of FY26, with growth across revenue, profit, and operational performance.
The company reported a consolidated net profit of ₹668 crore, marking a solid 21.45% year-on-year jump from ₹550 crore in the same quarter last year. Revenue also saw healthy growth, rising 11.2% to ₹3,371 crore compared to ₹3,031.8 crore a year ago. The pharmaceutical major’s EBITDA stood at ₹739 crore, up 21.35% from ₹609 crore, with margins improving to 21.9% from 20% in the previous year.
The domestic business remained the key growth driver, clocking sales of ₹2,265 crore, a 12% increase from the previous year, contributing 68.3% to total sales. According to IQVIA (SSA) data, the company outperformed the Indian Pharmaceutical Market (IPM) in seven therapies, including Gastrointestinal, Vitamins/Minerals/Nutrients, Pain Management, Anti-Diabetics, Neuro/CNS, Respiratory, and Dermatology, with growth ranging from 1.1x to 2.3x the market rate.
On the international front, sales stood at ₹1,053.9 crore, registering an 8.9% year-on-year rise. The US business contributed ₹698.2 crore, up 8.8% from last year and accounting for 21% of total sales. Non-US international markets generated ₹355.6 crore, up 9.1%, contributing 10.7% to total revenue. In the US market, Alkem filed its first Biologics License Application (BLA), received five ANDA approvals (including two tentative), and launched three new products during the quarter.
As of June 30, 2025, the company had filed 185 ANDAs, two NDAs, and one BLA with the USFDA, receiving approvals for 160 ANDAs (including 15 tentative) and both NDAs.
